Daily non-political popular news in brief.
Early treatment stops epilepsy in its tracks
12-13-2007 · EurekAlert!It is possible to suppress the development of epilepsy in genetically predisposed animals, which could open the door to treating epilepsy as a preventable disease.
Read more »
Keywords: treatment, stops, epilepsy, tracks, stop, track
« Previous | Next »
Similar news on "Early treatment stops epilepsy in its tracks":
- JCI table of contents: Feb. 1, 2007
02-01-2007 · EurekAlert!
This release contains summaries, links to PDFs and contact information for the following newsworthy papers to be published Feb. 1, 2007, in the JCI, including: New role in asthma for old drug; Tumor-reactive T cells boosted by hematopoietic stem cell transplantation; p21 stops HIV-1 in its tracks in hematopoietic stem cells; What makes epithelial cells change their identity?; NOTCHing up heart development; Stress response prevents neurodegeneration, and 4E-BP1 and 4E-BP2 stop mice getting fat.
Similar news · Read more »
- News tips from the Journal of Neuroscience
04-03-2007 · EurekAlert!
The following articles are featured in the upcoming issue of the Journal of Neuroscience: "Tracking Down Anomalous L Channels"; "An Interhemispheric Effect on Whisker Plasticity"; "Stop-and-Go Tract Tracing"; and "An Old Treatment for Epilepsy and a New Cellular Mechanism."
Similar news · Read more »
- Combination therapy stops loss of kidney function in rare genetic disease
07-25-2007 · EurekAlert!
A combination of two types of blood pressure-lowering drugs -- an angiotensin-converting enzyme inhibitor (ACEI) plus an angiotensin-receptor blocker (ARB), added to enzyme replacement therapy (ERT) with agalsidase-beta (Fabrazyme, Genzyme Corporation, Cambridge, Mass.) -- is the first treatment shown to stop progressive loss of kidney function in patients with severe kidney involvement due to the rare genetic disorder Fabry disease, reports a study in the September Journal of the American Society of Nephrology.
Similar news · Read more »
- New drug shows promise for treating epileptic seizures
04-05-2007 · EurekAlert!
A new study appearing in the latest issue of Epilepsia shows that a new drug called Eslicarbazepine (ESL) shows promise as a treatment for epilepsy patients whose symptoms remain uncontrolled with existing medications. A once-daily dose was shown to be most effective, offering patients added convenience as current treatments can involve several doses per day.
Similar news · Read more »
- JCI table of contents: Dec. 20, 2007
12-20-2007 · EurekAlert!
This release contains summaries, links to PDFs, and contact information for the following newsworthy papers to be published Dec. 20, 2007, in the JCI: "You can teach an old dog new tricks: antimalarial prevents cancer in mice"; "How an Atkins-like diet can treat epilepsy: Leptin attenuates rodent seizure severity"; "A new potential target in the treatment of a fatal brain disease"; "What AM I? AM is a regulator of vascular system functionality"; and others.
Similar news · Read more »
- JCI table of contents: Jan. 24, 2008
01-24-2008 · EurekAlert!
This release contains summaries, links to PDFs, and contact information for the following newsworthy papers to be published Jan. 24, 2008, in the JCI: TNF-alpha antagonist stops inflammation-induced colon cancer in its tracks; Building stronger bones, one stem cell at a time; Understanding a cause of Lou Gehrig’s disease; Genetic link to one form of a very common pediatric illness; and I can see clearly now Epo has come and gone.
Similar news · Read more »
- Ovation further advances development pipeline with new phase III epilepsy study
09-04-2007 · EurekAlert!
Ovation Pharmaceuticals is initiating a pivotal Phase III clinical trial for clobazam, a unique 1,5 benzodiazapine with significant anticonvulsant properties, as adjunctive treatment for patients with Lennox-Gastaut syndrome, one of the most severe forms of childhood epilepsy that frequently persists into adulthood. LGS is a rare and debilitating form of epilepsy. Clobazam represents one of five CNS launches Ovation expects over the next five years.
Similar news · Read more »
- New study shows promise in reducing surgical risks associated with surgical bleeding
08-10-2007 · EurekAlert!
Surgeons may have a new patient safety tool to stop moderate surgical bleeding without some of the concerns associated with the current standard blood-clotting treatment. New research published in the August issue of the Journal of the American College of Surgeons shows that recombinant human thrombin (rhThrombin) reduces the risk of surgical complications associated with the use of plasma-derived bovine thrombin (bThrombin), which is currently the only commercially available stand-alone thrombin used to improve clotting during surgical procedures and stop bleeding.
Similar news · Read more »
- TNF-alpha antagonist stops inflammation-induced colon cancer in its tracks
01-24-2008 · EurekAlert!
Individuals with the inflammatory bowel disease ulcerative colitis are at increased risk of developing colon cancer. New data have identified a central role for the soluble factor TNF-alpha in the development of colon cancer in mice induced to have inflammatory bowel disease. These data provide clear rationale for the idea that drugs antagonizing TNF-alpha (such as those used to treat rheumatoid arthritis) might reduce the risk of colon cancer in individuals with UC.
Similar news · Read more »
- One-off treatment to stop back pain -- Using patients' own stem cells
11-30-2006 · EurekAlert!
A University of Manchester researcher has developed a treatment for lower back pain using the patient's own stem cells, which could replace the use of strong painkillers or surgery that can cause debilitation, neither of which addresses the underlying cause.
Similar news · Read more »
